

# Medeor Pharma Limited

Annual Report and Unaudited Financial Statements  
for the Year Ended 30 September 2017

# Medeor Pharma Limited

## Contents

Company Information	<u>1</u>
Balance Sheet	<u>2</u> to <u>4</u>
Notes to the Financial Statements	<u>3</u>

# **Medeor Pharma Limited**

## **Company Information**

<b>Director</b>	Dr D J Tapolczay
<b>Registered office</b>	101 Teversham Drift Cambridge Cambs CB1 3LL
<b>Bankers</b>	HSBC St John's Innovation Park
<b>Accountants</b>	Full Spectrum Accountancy And Tax Limited Chartered Certified Accountants 101 Teversham Drift Cambridge Cambs CB1 3LL

# Medeor Pharma Limited

(Registration number: 05938602)

## Balance Sheet as at 30 September 2017

	Note	2017 £	(As restated) 2016 £
Fixed assets		-	331
Current assets		5,594	6,036
Creditors: Amounts falling due within one year		(20,000)	(20,000)
Net current liabilities		(14,406)	(13,964)
Total assets less current liabilities		(14,406)	(13,633)
Accruals and deferred income		(313)	(387)
		(14,719)	(14,020)
Capital and reserves		(14,719)	(14,020)

The notes on page 3 form an integral part of these financial statements.

(Registration number: 05938602)  
Balance Sheet as at 30 September 2017

**Medeor Pharma Limited**

**(Registration number: 05938602)**

**Balance Sheet as at 30 September 2017**

These financial statements have been prepared in accordance with the micro-entity provisions of the Companies Act 2006 and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

For the financial year ending 30 September 2017 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

- The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and
- The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

Approved and authorised by the director on 2 February 2018

.....

Dr D J Tapolczay

Director

The notes on page 3 form an integral part of these financial statements.  
Page 4

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.